All Real World Research OI Articles

Oncology Hematology Care, Inc. launched a one-year quality improvement project to implement and standardize comprehensive biomarker testing in patients with metastatic non-small cell lung cancer.

CAR T-cell therapies have ushered in a new era of treatment options for patients with certain hematologic malignancies. Thus, it is important to make these therapies accessible and affordable.

Adopting a human-centered approach to designing clinical trials that considers the preferences and experiences of rural patients with cancer and providers could increase patient enrollment and close care gaps.

A deep dive into 4 topics discussed during a series of interactive sessions at the ACCC 49th Annual Meeting and Cancer Center Business Summit: business and artificial intelligence technology, research and clinical trials, and precision medicine.

Actionable strategies for coordinating RECIST 1.1 at a community hospital.

Virginia Cancer Research Institute successfully implemented a cutting-edge clinical trials navigation program that improved the patient and provider experience and demonstrated a significant return on investment.

ACCC shares a look at the current NTRK testing landscape and identifies effective ways to optimize comprehensive biomarker testing in practice.

Climate change is typically seen through an environmental, political, or socioeconomic lens. Yet it should also be seen as a catastrophic health threat as it will have an effect on the delivery of comprehensive cancer care.

Highlights from the ACCC 49th Annual Meeting and Cancer Center Business Summit.

The Ohio State University Comprehensive Cancer Center developed the James Cancer Diagnostic Center, to deliver a comprehensive assessment of signs or symptoms of malignancy in a timely fashion.

Lankenau Medical Center operationalized this joint ASCO-ACCC implicit bias aimed at ensuring patients with cancer in underrepresented groups have equitable access to care and clinical trials.

Advancements in reproductive science has provided more options for women to take greater control of their reproductive future.

ACCC and AstraZeneca were recognized for their joint effort in the Rural Appalachian Lung Cancer Screening Initiative at the Cancer Moonshot: Goals Forum hosted, by the President and First Lady.

Technology-drive solutions will be essential in the future of cancer care, and providing the information, education and resources health care providers need to implement those solutions is important.

The HealthPartners Frauenshuh Cancer Center has safely incorporated cannabis in the treatment of patients with cancer.

Under ACORI, ACCC helps community oncology programs access the tools, knowledge sharing, effective practices, and peer mentorships that can increase their ability to offer clinical trials.

The summit brought together a diverse group of stakeholders to explore practical ways to strengthen and diversify oncology clinical trials.

One important step toward supporting the health of Indigenous Peoples was the opening of the Center for Indigenous Cancer Research (CICR) at Roswell Park Comprehensive Cancer Center in January 2020. Its mission: to reduce the impact of cancer on Indigenous communities regionally, nationally, and internationally.

One of the ways in which community oncology is helping to close gaps in cancer research is through participation in the National Cancer Institute Community Oncology Research Program clinical trials. The Lahey Health Cancer Institute, a part of the Beth Israel Lahey Health System, continues to expand access to clinical trials and, in particular, the NCI National Clinical Trials Network into the community by partnering with affiliated community hospitals.

Rather than fielding its annual Trending Now in Cancer Care survey while cancer programs were experiencing unprecedented challenges due to the extended public health emergency, ACCC chose to facilitate conversations with its members to capture the lived experiences of the most pertinent issues impacting oncology practice and care delivery.

Oncology Issues sat down with Dr. Schilsky to look back on his career and look forward to future research breakthroughs in this era of COVID-19 and beyond.

Assuming the ACCC presidency in March of 2020, just as the COVID-19 public health emergency went into effect, was certainly a dramatic way to enter office. That said, I am pleased with how much we have accomplished these last 12 months— despite the nationwide shutdown and ongoing pandemic.

This is the story of how a large independent practice in northwest Arkansas has nurtured its research program over several decades and is now able to offer patients access to phase I, II, and III trials close to home and their families.

With the enormous pressures of COVID-19, the ever-increasing complexity of oncology care, and the persistent social factors that lead to medical injustice, it is difficult to think about tackling even one more job. Yet, we must, we can, and we do. Today I want to mention four specific areas that all cancer programs need to be watching, thinking about, and preparing for.

With more than 25 years of oncology nursing experience and more than 18 years as an oncology nurse practitioner, Christa Braun-Inglis, MS, APRN-Rx, FNP-BC, AOCNP, has a wealth of clinical expertise.